Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCALOP selective chemoradiation in advanced localised pancreatic cancer
ISRCTN96169987Phase 2Completed
- Sponsor
- Cardiff University
- Start
- Jun 2008
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of gemcitabine and capecitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Cardiff University. Primary endpoint: Nine-month progression-free survival. Started Jun 2008; status: completed.
02
Drugs
gemcitabinecapecitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ISRCTN96169987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN96169987.